Natco seeks CDSCO approval for phase-III trial of Molnupiravir for COVID-19 treatment

By: |
April 26, 2021 11:11 AM

Drug major Natco Pharma on Monday said it has sought approval from the CDSCO in India for phase-III clinical trial of Molnupiravir capsules for the treatment of COVID-19 positive patients.

Drug major Natco Pharma, CDSCO in India, Molnupiravir capsules, Covid-19 patients, Natco Pharma, Compassionate use, treatment of covid-19The move will improve the local treatment options available and will positively impact the lives of people who are currently battling COVID-19 in India, Eli Lilly said in a statement. (Representational image)

Drug major Natco Pharma on Monday said it has sought approval from the Central Drugs Standard Control Organization (CDSCO) in India for phase-III clinical trial of Molnupiravir capsules for the treatment of COVID-19 positive patients. CDSCO is responsible for approval of drugs, conduct of clinical trials, laying down the standards for drugs, control over the quality of imported drugs in the country and coordination of the activities of state drug control organisations.

“Natco Pharma has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of phase-III clinical trial of Molnupiravir capsules for the treatment of COVID-19 positive patients,” the company said in a regulatory filing.
Natco Pharma said pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.

“Patients treated with Molnupiravir achieved response within five days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy, the company added. Natco is hoping that CDSCO would give emergency approval of this drug based on “compassionate use” for patients.

“Compassionate use” approval is given for investigational drugs so a patient with an immediately life-threatening condition can gain access to the drug, Natco Pharma said, adding that the company is ready to launch the product this month if approval is given.

Shares of Natco Pharma were trading 4.16 per cent higher at Rs 914.35 apiece on BSE.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1India’s 100 crore jabs success story silenced sceptics – PM Modi’s top quotes
2PM Modi lauds India’s vaccination drive as journey from ‘anxiety to assurance’
3Coronavirus (Covid-19) India Live News: 100 crore vaccination landmark not merely statistics, it’s a new chapter in history, says PM Modi in address to nation